Amy W Schulman's most recent trade in Fractyl Health Inc. was a trade of 22,500 Stock Option done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fractyl Health Inc. | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 22,500 | 22,500 | - | - | Stock Option | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 11,961 (0%) | 0% | 0 | Common Stock | |
| Fractyl Health Inc. | Amy W. Schulman | Director | Purchase of securities on an exchange or from another person at price $ 1.17 per share. | 13 Mar 2025 | 8,550 | 8,550 | - | 1.2 | 9,964 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.21 per share. | 13 Mar 2025 | 2,750 | 11,186 (0%) | 0% | 131.2 | 360,828 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2025 | 2,750 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Sale of securities on an exchange or to another person at price $ 240.00 per share. | 25 Jun 2024 | 8,500 | 8,436 (0%) | 0% | 240 | 2,040,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.21 per share. | 25 Jun 2024 | 8,500 | 16,936 (0%) | 0% | 131.2 | 1,115,285 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2024 | 8,500 | 2,750 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.83 per share. | 29 May 2024 | 30,000 | 30,136 (0%) | 0% | 66.8 | 2,004,900 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Sale of securities on an exchange or to another person at price $ 148.93 per share. | 29 May 2024 | 11,516 | 8,499 (0%) | 0% | 148.9 | 1,715,078 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Sale of securities on an exchange or to another person at price $ 148.21 per share. | 29 May 2024 | 10,121 | 20,015 (0%) | 0% | 148.2 | 1,500,033 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Sale of securities on an exchange or to another person at price $ 149.76 per share. | 29 May 2024 | 63 | 8,436 (0%) | 0% | 149.8 | 9,435 | Common Stock |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Fractyl Health Inc. | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 45,000 | 45,000 | - | - | Stock Option | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 136 | 0 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 136 | 136 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 136 | 136 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2021 | 1,814 | 1,814 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Amy W. Schulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) |